Reduced hepatic insulin sensitivity in metabolic syndromes, such as type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD) [5], may result directly from reduced insulin receptor numbers or indirectly from reduced insulin action via post-insulin receptor signalling pathway genes [6]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.